康莱特对晚期乳腺癌患者肿瘤标志物及生存质量的影响
|
摘要
目的探讨分析康莱特对晚期乳腺癌患者血清肿瘤标志物及生存质量的影响。方法选取我院收治的88例晚期乳腺癌患者,随机分为观察组和治疗组,各44例。对照组采用对症治疗和营养支持,观察组在对照组的基础上联合应用康莱特注射液。比较两组患者的治疗有效率、治疗前后血红蛋白、白细胞、血小板水平、肿瘤标志物水平以及Karnofsky评分。结果观察组患者治疗有效率显著高于对照组(P<0.05)。两组患者治疗后血红蛋白、白细胞、血小板计数、CA15-3、CA125、CEA水平均显著低于治疗前,而观察组显著高于对照组(P<0.05)。观察组患者Karnofsky评分改善率显著高于对照组(P<0.05)。结论应用康莱特治疗晚期乳腺癌,可提高治疗有效率、改善患者生存质量、降低肿瘤标志物水平,效果理想,值得在临床上推广。
Objective To investigate the effect of Kanglaite on serum tumor markers and quality of life in patients with advanced breast cancer. Methods Eighty-eight patients with advanced breast cancer enrolled in our hospital were randomly divided into control group and observation group. The control group got symptomatic treatment and nutritional support, while the observation group was added with Kanglaite injection on the basis of treatment of control group. The efficiency of treatment, changes of hemoglobin, leukocyte, platelet and tumor markers before and after treatment, and the Karnofsky scores were compared between the two groups. Results The total efficiency of the observation group was significantly higher than that of the control group(P<0.05). The levels of hemoglobin, leukocyte, CA15-3, CA125 and CEA, and the platelet count of patients after treatment all were lower than those before treatment(P<0.05) in both groups. In addition, they were all lower in the observation group than in the control group after treatment(P<0.05). The observation group also achieved a higher improvement rate of Karnofsky score than the control group(P<0.05). Conclusion Kanglaite had good effects in the treatment of advanced breast cancer. It could strengthen the treatment efficiency, reduce the levels of tumor markers, and improve the life quality of patients, so it is worthy of clinical promotion.
Objective To investigate the effect of Kanglaite on serum tumor markers and quality of life in patients with advanced breast cancer. Methods Eighty-eight patients with advanced breast cancer enrolled in our hospital were randomly divided into control group and observation group. The control group got symptomatic treatment and nutritional support, while the observation group was added with Kanglaite injection on the basis of treatment of control group. The efficiency of treatment, changes of hemoglobin, leukocyte, platelet and tumor markers before and after treatment, and the Karnofsky scores were compared between the two groups. Results The total efficiency of the observation group was significantly higher than that of the control group(P<0.05). The levels of hemoglobin, leukocyte, CA15-3, CA125 and CEA, and the platelet count of patients after treatment all were lower than those before treatment(P<0.05) in both groups. In addition, they were all lower in the observation group than in the control group after treatment(P<0.05). The observation group also achieved a higher improvement rate of Karnofsky score than the control group(P<0.05). Conclusion Kanglaite had good effects in the treatment of advanced breast cancer. It could strengthen the treatment efficiency, reduce the levels of tumor markers, and improve the life quality of patients, so it is worthy of clinical promotion.
引文
[1]Cho GY, Moy L, Kim SG, et al. Evaluation of breast cancer using intravoxel incoherent motion(IVIM)histogram analysis:comparison with malignant status, histological subtype,and molecular prognostic factors[J]. Eur Radiol, 2016,26(8):2547-2558. doi:10.1007/s00330-015-4087-3.
[2]Wang X, Cheng K, Han Y, et al. Effects of Psoralen as an Anti-tumor Agent in Human Breast Cancer MCF-7/ADR Cells[J]. Biol Pharm Bull, 2016, 39(5):815-822. doi:10.1248/bpb. b15-00957.
[3]刘春慧,王湘川,莫静资,等.舒尼替尼对晚期肾癌患者的疗效及预后的影响[J].肿瘤药学, 2017, 7(2):195-199.doi:10.3969/j. issn.2095-1264.2017.02.13.
[4]Pandey N, Pandey-Rai S. Updates on artemisinin:an insight to mode of actions and strategies for enhanced global production[J]. Protoplasma, 2016, 253(1):15-30. doi:10.1007/s00709-015-0805-6.
[5]Poloni TE, Alimehmeti R, Galli A, et al."Malignant"foot drop:Enzinger epithelioid sarcoma of the common fibular nerve[J]. Muscle Nerve, 2016, 54(4):805-806. doi:10.1002/mus.25134.
[6]Starbuck KD, Drake RD, Budd GT, et al. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors:Single-institution Experience and Review of the Literature[J]. Anticancer Res, 2016,36(11):6161-6164.
[7]Yamamoto N, Nokihara H, Yamada Y, et al. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors[J]. Invest New Drugs, 2017, 35(2):207-216. doi:10.1007/s10637-016-0411-2.
[8]张宇琳,吴涛,刘鸿翔,等.手术联合新辅助化疗对局部晚期食管癌患者的疗效及生存时间研究[J].肿瘤药学, 2017,7(3):300-303. doi:10.3969/j. issn.2095-1264.2017.03.09.
[9]Fenstermaker RA, Ciesielski MJ, Qiu J, et al. Clinical study of a survivin long peptide vaccine(SurVaxM)in patients with recurrent malignant glioma[J]. Cancer Immunol Immunother, 2016, 65(11):1339-1352.
[10]Hude I, Sasse S, Engert A, et al. The emerging role of immune checkpoint inhibition in malignant lymphoma[J].Haematologica, 2017, 102(1):30-42. doi:10.3324/haematol.2016.150656.
[11]H?lzel M, Landsberg J, Glodde N, et al. A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells[J]. Cancer Res, 2016, 76(2):251-263. doi:10.1158/0008-5472.CAN-15-1090.
[12]Wang Y, Wu L, Tian C, et al. PD-1-PD-L1 immunecheckpoint blockade in malignant lymphomas[J].Ann Hematol, 2018, 97(2):229-237. doi:10.1007/s00277-017-3176-6.
[13]Lievense LA, Cornelissen R, Bezemer K, et al. Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression[J]. J Thorac Oncol,2016, 11(10):1755-1764. doi:10.1016/j. jtho.2016.06.021.
[14]Zhu H, Luo H, Shen Z, et al. Transforming growth factor-β1in carcinogenesis, progression, and therapy in cervical cancer[J]. Tumour Biol, 2016, 37(6):7075-7083. doi:10.1007/s13277-016-5028-8.
[15]Kawahara T, Kashiwagi E, Li Y, et al. Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis[J]. Mol Carcinog,2016, 55(2):161-169. doi:10.1002/mc.22265.
[2]Wang X, Cheng K, Han Y, et al. Effects of Psoralen as an Anti-tumor Agent in Human Breast Cancer MCF-7/ADR Cells[J]. Biol Pharm Bull, 2016, 39(5):815-822. doi:10.1248/bpb. b15-00957.
[3]刘春慧,王湘川,莫静资,等.舒尼替尼对晚期肾癌患者的疗效及预后的影响[J].肿瘤药学, 2017, 7(2):195-199.doi:10.3969/j. issn.2095-1264.2017.02.13.
[4]Pandey N, Pandey-Rai S. Updates on artemisinin:an insight to mode of actions and strategies for enhanced global production[J]. Protoplasma, 2016, 253(1):15-30. doi:10.1007/s00709-015-0805-6.
[5]Poloni TE, Alimehmeti R, Galli A, et al."Malignant"foot drop:Enzinger epithelioid sarcoma of the common fibular nerve[J]. Muscle Nerve, 2016, 54(4):805-806. doi:10.1002/mus.25134.
[6]Starbuck KD, Drake RD, Budd GT, et al. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors:Single-institution Experience and Review of the Literature[J]. Anticancer Res, 2016,36(11):6161-6164.
[7]Yamamoto N, Nokihara H, Yamada Y, et al. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors[J]. Invest New Drugs, 2017, 35(2):207-216. doi:10.1007/s10637-016-0411-2.
[8]张宇琳,吴涛,刘鸿翔,等.手术联合新辅助化疗对局部晚期食管癌患者的疗效及生存时间研究[J].肿瘤药学, 2017,7(3):300-303. doi:10.3969/j. issn.2095-1264.2017.03.09.
[9]Fenstermaker RA, Ciesielski MJ, Qiu J, et al. Clinical study of a survivin long peptide vaccine(SurVaxM)in patients with recurrent malignant glioma[J]. Cancer Immunol Immunother, 2016, 65(11):1339-1352.
[10]Hude I, Sasse S, Engert A, et al. The emerging role of immune checkpoint inhibition in malignant lymphoma[J].Haematologica, 2017, 102(1):30-42. doi:10.3324/haematol.2016.150656.
[11]H?lzel M, Landsberg J, Glodde N, et al. A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells[J]. Cancer Res, 2016, 76(2):251-263. doi:10.1158/0008-5472.CAN-15-1090.
[12]Wang Y, Wu L, Tian C, et al. PD-1-PD-L1 immunecheckpoint blockade in malignant lymphomas[J].Ann Hematol, 2018, 97(2):229-237. doi:10.1007/s00277-017-3176-6.
[13]Lievense LA, Cornelissen R, Bezemer K, et al. Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression[J]. J Thorac Oncol,2016, 11(10):1755-1764. doi:10.1016/j. jtho.2016.06.021.
[14]Zhu H, Luo H, Shen Z, et al. Transforming growth factor-β1in carcinogenesis, progression, and therapy in cervical cancer[J]. Tumour Biol, 2016, 37(6):7075-7083. doi:10.1007/s13277-016-5028-8.
[15]Kawahara T, Kashiwagi E, Li Y, et al. Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis[J]. Mol Carcinog,2016, 55(2):161-169. doi:10.1002/mc.22265.